Depression, antidepressant use, and breast cancer incidence: results from the E3N prospective cohort
Psychiatry and Clinical Neurosciences · 2025
DOI: 10.1111/pcn.13852 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychiatry and Clinical Neurosciences, 2025. Verfasst von Romain Colle und 7 weiteren Autor:innen. Beteiligte Einrichtung: MOODS Team, INSERM 1018, CESP, Faculté de Médecine Paris-Saclay, Univ Paris Saclay, Le Kremlin Bicêtre, France. Hauptthemen laut MEDLINE: Breast Neoplasms, Depression, Antidepressive Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: French League against Cancer, Ligue Contre le Cancer.
Themen: Depression
Abstract (Originalsprache)
Aim
Depression and antidepressant drugs may both impact breast cancer incidence, potentially in opposite directions. The few epidemiological studies attempting to disentangle their effects have been inconclusive. We aimed to assess within the same prospective cohort the association between depression, antidepressant use, and breast cancer risk, while controlling for potential confounders.
Methods
The study population included 47,791 women from the E3N (Etude Epidémiologique Auprès de Femmes de la Mutuelle Générale de l'Education Nationale) prospective cohort, born between 1925 and 1950 and followed for breast cancer incidence from 2005 to 2014. Depression was defined by a Center for Epidemiologic Studies‐Depression Scale (CES‐D) score ≥17. Exposure to antidepressants was identified from drug claims data available from 2004 onwards. Hazard ratios (HRs) and 95% confidence intervals (CIs) for invasive breast cancer were calculated using Cox proportional hazards models adjusted for breast cancer risk factors. Antidepressant exposure was time‐varying.
Results
During a mean follow‐up of 7.2 years, 1365 breast cancers occurred. Depression was associated with a higher incidence of breast cancer (HR, 1.14 [95% CI, 1.01–1.29]), while exposure to antidepressants was associated with a lower risk (HR, 0.85 [95% CI, 0.74–0.98]). No association was observed for treatment durations
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MOODS Team, INSERM 1018, CESP, Faculté de Médecine Paris-Saclay, Univ Paris Saclay, Le Kremlin Bicêtre, France.
- Groupe Hospitalier Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Le Kremlin Bicêtre, France.
- UVSQ, Inserm, Gustave Roussy, CESP, Université Paris-Saclay, Villejuif, France.
- UVSQ, Inserm, CESP, Université Paris-Saclay, Villejuif, France.
- Department of Statistics, Computer Science, Applications "G. Parenti", University of Florence, Florence, Italy.
ORCID-Profile: Romain Colle, Agnès Fournier
Förderung
- French League against Cancer
- Ligue Contre le Cancer
Zitieren
APA
Colle, R., Deflesselle, E., Mohamed, O., Falissard, B., Severi, G., Fournier, A., Boutron-Ruault, M. C., & Corruble, E. (2025). Depression, antidepressant use, and breast cancer incidence: results from the E3N prospective cohort. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13852
Vancouver
Colle R, Deflesselle E, Mohamed O, Falissard B, Severi G, Fournier A, et al. Depression, antidepressant use, and breast cancer incidence: results from the E3N prospective cohort. Psychiatry and Clinical Neurosciences. 2025. doi:10.1111/pcn.13852
BibTeX
@article{Colle2025,
author = {Colle, Romain and Deflesselle, Eric and Mohamed, Océane and Falissard, Bruno and Severi, Gianluca and Fournier, Agnès and Boutron-Ruault, Marie-Christine and Corruble, Emmanuelle},
title = {Depression, antidepressant use, and breast cancer incidence: results from the E3N prospective cohort},
journal = {Psychiatry and Clinical Neurosciences},
year = {2025},
doi = {10.1111/pcn.13852}
}
EUVIMED